Clinical Trial Outcomes: Citius Pharma's primary assets, such as Mino-Lok and I/ONTAK, are still in clinical development. Failure to achieve primary endpoints, unexpected adverse events, or significant delays in trials could lead to a complete loss of investment and prevent regulatory approval.

Regulatory Approval Uncertainties: Even with positive clinical trial data, there is no guarantee that regulatory bodies like the FDA will grant approval for commercialization. The approval process is complex and can be lengthy, with potential for requests for additional studies or data.

Intense Market Competition: The therapeutic areas targeted by Citius Pharma's drug candidates, such as critical care anti-infectives and oncology, are highly competitive. Established pharmaceutical companies and new entrants could develop more effective or cheaper alternatives, eroding market share.